Seeing the immune battle inside lung tumors: a new imaging tracer under the microscope

NCT ID NCT05157659

Ongoing Diagnosis Sponsor: Amsterdam UMC, location VUmc Source: ClinicalTrials.gov ↗

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This study tests a new PET imaging tracer called [18F]F-AraG to see if it can spot activated T-cells inside non-small cell lung cancer tumors. Researchers will scan about 10 patients with resectable lung cancer, then compare the tracer's uptake with lab analysis of the removed tumor tissue. The goal is to understand how well this tracer works for imaging immune activity, which could eventually help tailor treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: A PET scan using the experimental tracer [18F]F-AraG to visualize activated T-cells in tumors.
What this could lead to: If successful, this imaging method could help doctors see how active the immune system is inside tumors, potentially guiding immunotherapy decisions.
What could go wrong: This is a small early imaging study, so the tracer may not reliably reflect T-cell activity, and results may not translate to routine clinical use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Amsterdam UMC, location VU University Medical Center

Amsterdam, Nederland, 1081HV, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.